Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone:** +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk
Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of
the company.

- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Additional Details

Publisher : Global Data
Reference : GDPH40875D
Number of Pages : 41
Report Format : PDF
Publisher Information :
Table Of Contents for Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

- Table of Contents Table of Contents
- List of Tables
- List of Figures
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- 5Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
- 6Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
- 7Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
- 8Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
- 9Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details
- 10Asset Purchase
- 11Vernalis Acquires US rights to MOXATAG from Pragma Pharma
- 12Partnerships
- 13Vernalis and Daiichi Sankyo Enter into Agreement
- 14Vernalis and Servier Enter into Discovery Agreement
- 15Vernalis Enters into Research Agreement with Taisho Pharma
- 16Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei
- 17Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier
- 18Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies
- 19Licensing Agreements
- 20Corvus Pharma Amends Licensing Agreement With Vernalis
- 21CTI BioPharma Enters into Licensing Agreement with Vernalis
- 22toosedstat
- 23Vernalis Enters into Licensing Agreement with RedoxTherapies
- 2419Equity Offering
- 25Vernalis Raises USD58 Million in Private Placement of Shares
- 26Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million
- 2721Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million
- 2822Acquisition
- 2923Ligand Pharma Acquires Vernalis
- 3024Vernalis Plc - Key Competitors
- 3125Vernalis Plc - Key Employees
- 3226Vernalis Plc - Locations And Subsidiaries
- 3327Head Office
- 3427Other Locations & Subsidiaries
- 3527Recent Developments
- 3628Financial Announcements
- 3728Mar 28, 2018: Vernalis Reports Unaudited Interim Results For The Six Months Ended 31 December 2017
- 3828Sep 12, 2017: Vernalis: Results Announcement for the year ended 30 June 2017
- 3928Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results
- 4028Feb 21, 2017: Vernalis: Unaudited Interim Results for the six months ended 31 December 2016
- 4136Corporate Communications
- 4339Appendix
- 4441Methodology
- 4541About GlobalData
- 4641Contact Us
- 4741Disclaimer

© BioPortfolio
Limited - 2019

https://www.bioportfolio.co.uk/product/228321
pdb@bioportfolio.co.uk to order
Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Vernalis Plc, Deals By Therapy Area, 2012 to YTD 2018
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Vernalis Acquires US rights to MOXATAG from Pragma Pharma
Vernalis and Daiichi Sankyo Enter into Agreement
Vernalis and Servier Enter into Discovery Agreement
Vernalis Enters into Research Agreement with Taisho Pharma
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies
Corvus Pharma Amends Licensing Agreement With Vernalis
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat
Vernalis Enters into Licensing Agreement with RedoxTherapies
Vernalis Raises USD58 Million in Private Placement of Shares
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million
Ligand Pharma Acquires Vernalis
Vernalis Plc, Key Competitors
Vernalis Plc, Key Employees
Vernalis Plc, Subsidiaries
List Of Figures, Charts and Diagrams in Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

List of Figures

Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
How to Buy...

Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/228321

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: _____________________________________________________________
Job Title: ______________________________________________________________
Your Email: _____________________________________________________________
Your Contact Phone: _____________________________________________________
Company Name: _________________________________________________________
Address: ________________________________________________________________
Post/Zip Code: ___________________________________________________________
Country: _________________________________________________________________
P.O. Number: ____________________________________________________________
Any Other Instructions: __________________________________________________

Pricing Options: (please tick one)
○ $220 | Single User Price
○ $440 | Site License Price
○ $660 | Global License Price

Payment Options: (please tick one)
○ Online Credit Card (we will email you the invoice with a payment link)
○ Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: ____________________________________________________

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.